Novel applications of histopathological markers to distinguish prognostic subgroups in colorectal adenocarcinoma

References

• Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer. Lancet. 2019;394(10207):1–12. doi: 10.1016/S0140-6736(19)32319-0.
   PubMed Web of Science ®Google Scholar
• Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022;135(5):584–590. doi: 10.1097/CM9.0000000000002108.
   PubMed Web of Science ®Google Scholar
• Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471–1474. doi: 10.1245/s10434-010-0985-4.
   PubMed Web of Science ®Google Scholar
• Betge J, Harbaum L, Pollheimer MJ, et al. Lymph node retrieval in colorectal cancer: determining factors and prognostic significance. Int J Colorectal Dis. 2017;32(7):991–998. doi: 10.1007/s00384-017-2778-8.
   PubMed Web of Science ®Google Scholar
• Berberoglu U. Prognostic significance of total lymph node number in patients with T1-4N0M0 colorectal cancer. Hepato-gastroenterology. 2004;51(60):1689–1693.
   PubMedGoogle Scholar
• Cao Y, Deng S, Yan L, et al. Perineural invasion is associated with poor prognosis of colorectal cancer: a retrospective cohort study. Int J Colorectal Dis. 2020;35(6):1067–1075. doi: 10.1007/s00384-020-03566-2.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Suwa K, Ogawa M, et al. Adjuvant chemotherapy for the perineural invasion of colorectal cancer. J Surg Res. 2015;199(1):84–89. doi: 10.1016/j.jss.2015.03.101.
   PubMed Web of Science ®Google Scholar
• Melling N, Kowitz CM, Simon R, et al. High Ki67 expression is an independent good prognostic marker in colorectal cancer. J Clin Pathol. 2016;69(3):209–214. doi: 10.1136/jclinpath-2015-202985.
   PubMed Web of Science ®Google Scholar
• Tong G, Zhang G, Liu J, et al. Cutoff of 25% for Ki67 expression is a good classification tool for prognosis in colorectal cancer in the AJCC8 stratification. Oncology Reports. 2020;43(4):1187–1198.
   PubMed Web of Science ®Google Scholar
• Zhu G, Pei L, Xia H, et al. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer. Mol Cancer. 2021;20(1):143. doi: 10.1186/s12943-021-01441-4.
   PubMed Web of Science ®Google Scholar
• Damit D, Patnaik R, Chaw LL, et al. KRAS mutation: characterization and its impact on survival outcome of patients with metastatic colorectal cancer. Front Biosci (Landmark Ed). 2022;27(7):213. doi: 10.31083/j.fbl2707213.
   PubMed Web of Science ®Google Scholar
• Luo H, Lu J, Bai Y, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and Progression-Free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. Jama. 2021;326(10):916–925. doi: 10.1001/jama.2021.12836.
   PubMed Web of Science ®Google Scholar
• Steffen P, Li J, Chandra J, et al. Molecular features of lymph node metastasis in T1/2 colorectal cancer from Formalin-Fixed Paraffin-Embedded archival specimens. J Proteome Res. 2021;20(2):1304–1312. doi: 10.1021/acs.jproteome.0c00693.
   PubMed Web of Science ®Google Scholar
• Benson AB, Venook AP, Al-Hawary MM, et al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(3):329–359. doi: 10.6004/jnccn.2021.0012.
   PubMed Web of Science ®Google Scholar
• Al-Sukhni E, Attwood K, Gabriel EM, et al. Lymphovascular and perineural invasion are associated with poor prognostic features and outcomes in colorectal cancer: a retrospective cohort study. Int J Surg. 2017;37:42–49. doi: 10.1016/j.ijsu.2016.08.528.
   PubMed Web of Science ®Google Scholar
• Huh JW, Kim HR, Kim YJ. Lymphovascular or perineural invasion may predict lymph node metastasis in patients with T1 and T2 colorectal cancer. J Gastrointest Surg. 2010;14(7):1074–1080. doi: 10.1007/s11605-010-1206-y.
   PubMed Web of Science ®Google Scholar
• Liu L, Liu J, Wang J, et al. Machine learning revealed molecular classification of colorectal cancer with negative lymph node metastasis. Biomarkers. 2022;27(1):86–94. doi: 10.1080/1354750X.2021.2016971.
   PubMed Web of Science ®Google Scholar
• Mahar AL, Compton C, Halabi S, et al. Personalizing prognosis in colorectal cancer: a systematic review of the quality and nature of clinical prognostic tools for survival outcomes. J Surg Oncol. 2017;116(8):969–982. doi: 10.1002/jso.24774.
   PubMed Web of Science ®Google Scholar
• Lumachi F, Orlando R, Marino F, et al. Expression of p53 and Ki-67 as prognostic factors for survival of men with colorectal cancer. Anticancer Res. 2012;32(9):3965–3967.
   PubMed Web of Science ®Google Scholar
• Ren JQ, Liu JW, Chen ZT, et al. Prognostic value of the lymph node ratio in stage III colorectal cancer. Chin J Cancer. 2012;31(5):241–247. doi: 10.5732/cjc.011.10374.
   PubMedGoogle Scholar
• Walker AS, Johnson EK, Maykel JA, et al. Future directions for the early detection of colorectal cancer recurrence. J Cancer. 2014;5(4):272–280. doi: 10.7150/jca.8871.
   PubMed Web of Science ®Google Scholar